Drug
Tinzaparin
Tinzaparin: highest development phase Post-Market, developed by LEO Pharma. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- LEO Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tinzaparin NCT01930396 | Post-Market | Kidney Failure, Chronic |
| tinzaparin NCT04794569 | Post-Market | Deep Vein Thrombosis |
Latest
No recent events.
Follow Tinzaparin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.